Press Release Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights 6 hours ago
Press Release Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy Aug 5